Cupid Shares Hit 52-Week High as Company Raises FY27 Guidance
Cupid shares climbed over 3% to reach a fresh 52-week high of Rs 368 apiece on the National Stock Exchange on Friday, extending a multi-year rally that spans more than 15,410% gain over five years, economictimes.indiatimes.com reported.
Fourth Consecutive Trading Session of Gains
The stock advanced for the fourth straight session, building on a weekly gain exceeding 16%. Over the past month, Cupid shares have risen 30%. Year-to-date in 2026, the equity has surged 246%, gaining 657% over the past year despite broader market weakness.
This market activity accompanies an upward revision in corporate financial targets. Earlier this month, management adjusted its fiscal year 2027 outlook for the second time in less than two weeks. The condom-maker now projects Rs 800 crore in revenue and Rs 250 crore in net profit for FY27.
Projected Revenue Milestones for Q2 FY27
Business momentum remains strong heading into the second half of the fiscal year. Total revenue for Q2 FY27 is expected to cross Rs 200 crore, according to company statements.
Improved visibility across both domestic and international markets drove the guidance upgrade. Sustained performance across key business verticals underpinned the revisions.
Palava Facility and FMCG Growth Drive FY27 Outlook
Management attributes the revised FY27 outlook to several operational catalysts. These include anticipated growth extending through the third and fourth quarters, wider reach in institutional and private markets, and ongoing expansion within the domestic fast-moving consumer goods division.
Progress toward the imminent operationalization of the Palava manufacturing facility forms a core part of this strategy. The new site aims to enhance production capacity, operational flexibility, and supply chain capabilities for both domestic and international distribution channels.
Future Distribution and Portfolio Strategy
Looking ahead, the company intends to scale its domestic FMCG distribution to deepen market penetration across modern trade, general trade, and pharmacy networks. Plans also involve broadening the healthcare and personal care portfolio via new product introductions, securing necessary regulatory approvals, and pursuing wider commercialization.
International operations remain a priority. Cupid plans to grow institutional, government, and private-market opportunities across multiple geographies while building regional manufacturing platforms through a proposed South African venture designed to serve as a potential base for wider international market expansion.
Strategic healthcare opportunities will also be explored through partnerships and investments intended to strengthen the existing product ecosystem. Cupid manufactures and supplies male and female condoms, water-based lubricant jelly, and IVD kits.